DE69816634D1 - Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis - Google Patents

Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis

Info

Publication number
DE69816634D1
DE69816634D1 DE69816634T DE69816634T DE69816634D1 DE 69816634 D1 DE69816634 D1 DE 69816634D1 DE 69816634 T DE69816634 T DE 69816634T DE 69816634 T DE69816634 T DE 69816634T DE 69816634 D1 DE69816634 D1 DE 69816634D1
Authority
DE
Germany
Prior art keywords
cartilage
matrix protein
rheumatoid arthritis
treating rheumatoid
oligomer matrix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69816634T
Other languages
English (en)
Other versions
DE69816634T2 (de
Inventor
Dick Heinegard
C Lorentzen
Lars Klareskog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE69816634D1 publication Critical patent/DE69816634D1/de
Application granted granted Critical
Publication of DE69816634T2 publication Critical patent/DE69816634T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69816634T 1997-04-15 1998-04-14 Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis Expired - Lifetime DE69816634T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9701409 1997-04-15
SE9701409A SE9701409D0 (sv) 1997-04-15 1997-04-15 Treatment of rheumatoid arthritis
PCT/SE1998/000682 WO1998046253A1 (en) 1997-04-15 1998-04-14 Use of cartilage oligomeric matrix protein for the treatment of rheumatoid arthritis

Publications (2)

Publication Number Publication Date
DE69816634D1 true DE69816634D1 (de) 2003-08-28
DE69816634T2 DE69816634T2 (de) 2004-06-03

Family

ID=20406587

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816634T Expired - Lifetime DE69816634T2 (de) 1997-04-15 1998-04-14 Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis

Country Status (21)

Country Link
EP (1) EP1019078B1 (de)
JP (1) JP2001520647A (de)
KR (1) KR20010006352A (de)
CN (1) CN1260721A (de)
AT (1) ATE245438T1 (de)
AU (1) AU746221B2 (de)
BR (1) BR9808591A (de)
CA (1) CA2286791A1 (de)
DE (1) DE69816634T2 (de)
EE (1) EE9900464A (de)
HU (1) HUP0002231A3 (de)
ID (1) ID24561A (de)
IL (1) IL132354A0 (de)
IS (1) IS5210A (de)
NO (1) NO995004L (de)
NZ (1) NZ338084A (de)
PL (1) PL336163A1 (de)
SE (1) SE9701409D0 (de)
SK (1) SK141399A3 (de)
TR (1) TR199902564T2 (de)
WO (1) WO1998046253A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849594B1 (en) * 1999-06-30 2005-02-01 John Lawler Purification and use of human recombinant cartilage oligomeric matrix protein
SE9904236D0 (sv) 1999-11-22 1999-11-22 Ana Mar Diagnostics Ab Immunoassay
KR100429288B1 (ko) * 2001-11-23 2004-04-29 장오기계 주식회사 전사인쇄장치
CN100417415C (zh) * 2006-06-28 2008-09-10 文彦春 浸润治疗关节炎的药物
DK2867679T3 (en) 2012-06-28 2018-08-13 Nordic Bioscience As DETERMINATION OF PATHOLOGICAL SHOWER COMPOSITION

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5872094A (en) * 1993-01-06 1999-02-16 The General Hospital Corporation Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface

Also Published As

Publication number Publication date
HUP0002231A2 (hu) 2000-11-28
HUP0002231A3 (en) 2002-09-30
BR9808591A (pt) 2000-05-23
AU7093898A (en) 1998-11-11
SE9701409D0 (sv) 1997-04-15
NO995004D0 (no) 1999-10-14
KR20010006352A (ko) 2001-01-26
NO995004L (no) 1999-10-14
EE9900464A (et) 2000-04-17
TR199902564T2 (xx) 2000-02-21
ID24561A (id) 2000-07-27
IS5210A (is) 1999-10-12
ATE245438T1 (de) 2003-08-15
DE69816634T2 (de) 2004-06-03
CA2286791A1 (en) 1998-10-22
CN1260721A (zh) 2000-07-19
EP1019078A1 (de) 2000-07-19
SK141399A3 (en) 2000-08-14
AU746221B2 (en) 2002-04-18
EP1019078B1 (de) 2003-07-23
NZ338084A (en) 2001-07-27
IL132354A0 (en) 2001-03-19
PL336163A1 (en) 2000-06-05
WO1998046253A1 (en) 1998-10-22
JP2001520647A (ja) 2001-10-30

Similar Documents

Publication Publication Date Title
NO20006718L (no) Proteaseinhibitorer
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE69507029D1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin-vermittelten krankheiten
ATE275343T1 (de) Verarbeitung von pflantzlichem material mit xylanase
ATE353914T1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DE69426471T2 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
ATE254924T1 (de) Stör-notokord zur verminderung der symptome / behandlung von arthritis
DE69816634D1 (de) Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE190839T1 (de) Verwendung von prodelphidinen zur behandlung von arthrose
ATE251631T1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
GR3033698T3 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections.
DE50001730D1 (de) Gemisch zur behandlung von abfallmaterial
AP9701142A0 (en) 4,4-(Disubstituted) cyclohexan-1-ols monomers and related compounds.
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
ATE311901T1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE69408664T2 (de) Zusammensetzungen zur behandlung von geernteter pflanzenmaterial
ATE55252T1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition